200 related articles for article (PubMed ID: 34069498)
41. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
42. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
[TBL] [Abstract][Full Text] [Related]
43. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
44. The estrogen receptor: a model for molecular medicine.
Jensen EV; Jordan VC
Clin Cancer Res; 2003 Jun; 9(6):1980-9. PubMed ID: 12796359
[TBL] [Abstract][Full Text] [Related]
45. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?
Jordan VC
J Clin Oncol; 2008 Jun; 26(18):3073-82. PubMed ID: 18519949
[TBL] [Abstract][Full Text] [Related]
46. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
47. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
[TBL] [Abstract][Full Text] [Related]
48. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor.
Landry M; Di Paolo T
Brain Res Mol Brain Res; 2003 Apr; 112(1-2):82-9. PubMed ID: 12670705
[TBL] [Abstract][Full Text] [Related]
49. [Mechanism of acquired antiestrogen resistance and its management in breast cancer].
Iino Y; Maemura M; Morishita Y
Nihon Rinsho; 1997 May; 55(5):1149-54. PubMed ID: 9155167
[TBL] [Abstract][Full Text] [Related]
50. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
51. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
52. Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator.
Zhang JX; Labaree DC; Mor G; Hochberg RB
J Clin Endocrinol Metab; 2004 Jul; 89(7):3527-35. PubMed ID: 15240642
[TBL] [Abstract][Full Text] [Related]
53. Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.
Zheng H; Kangas L; Härkönen PL
J Steroid Biochem Mol Biol; 2004 Feb; 88(2):143-56. PubMed ID: 15084346
[TBL] [Abstract][Full Text] [Related]
54. Are estrogen receptor content in breast cancer and effects of tamoxifen on sex hormone-binding globulin markers for individual estrogen sensitivity?
Löfgren L; von Schoultz E; Fernstad R; von Schoultz B; Carlström K
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):76-9. PubMed ID: 16621526
[TBL] [Abstract][Full Text] [Related]
55. Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Sismondi P; Biglia N; Ponzone R; Fuso L; Scafoglio C; Cicatiello L; Ravo M; Weisz A; Cimino D; Altobelli G; Friard O; De Bortoli M
Maturitas; 2007 May; 57(1):50-5. PubMed ID: 17395409
[TBL] [Abstract][Full Text] [Related]
56. Tamoxifen aziridines: effective inactivators of the estrogen receptor.
Robertson DW; Wei LL; Hayes JR; Carlson KE; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 1981 Oct; 109(4):1298-300. PubMed ID: 7285873
[TBL] [Abstract][Full Text] [Related]
57. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
59. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
60. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
